HLN (HLN) Stock Price & Analysis
HLN (HLN) rose 2.59% to USD 9.12 as of June 9, 2026 at 23:43 UTC, according to Nexqual real-time market data.
HLN last closed at USD 8.89; the session ranged USD 8.94–9.13 on volume of 8,907,737 shares. Market capitalization is $40.26B, with a 52-week range of USD 8.65–11.28 (NYQ). Source: Nexqual, June 9, 2026 at 23:43 UTC.
Key Statistics (as of June 9, 2026 at 23:43 UTC)
| Price | USD 9.12 |
|---|---|
| Change | ▲ 2.59% (up) |
| Previous Close | USD 8.89 |
| Open | USD 8.96 |
| Day Range | USD 8.94 – 9.13 |
| 52-Week Range | USD 8.65 – 11.28 |
| Volume | 8,907,737 shares |
| Market Cap | $40.26B |
| Exchange | NYQ |
Technical Analysis (HLN)
Nexqual's technical model rates HLN "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:43 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.1 (neutral) |
| vs SMA50 | Below (USD 9.38) |
| MACD | -0.11 (negative) |
Analyst Ratings (HLN)
Wall Street analysts rate HLN "Buy" based on 5 analysts, with a mean price target of USD 11.74 (range USD 10–13.85), per Nexqual as of June 9, 2026 at 23:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11.74 |
| High Target | USD 13.85 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (HLN)
| Revenue Estimate | $2.87B |
|---|
Source: Nexqual, June 9, 2026 at 23:43 UTC.
Financials & Fundamentals (HLN)
| Total Revenue | $11.03B |
|---|---|
| Revenue Growth (YoY) | +0.60% |
| Gross Margin | +64.77% |
| Operating Margin | +23.17% |
| Profit Margin | +15.11% |
| ROE | +10.27% |
| Debt / Equity | 52.37 |
| Current Ratio | 0.92 |
| Total Cash | $1.35B |
| Total Debt | $8.63B |
| Free Cash Flow | $1.40B |
Source: Nexqual, June 9, 2026 at 23:43 UTC.
Financial Health Score (HLN)
Nexqual rates HLN's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:43 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 65%, operating 23% |
| Balance Sheet | Mixed — $1.35B cash vs $8.63B debt |
| Cash Flow | Solid — FCF $1.40B, 13% margin |
| Efficiency | Mixed — ROE 10%, ROA 4.7% |
Ownership (HLN)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +13.26% |
| Shares Outstanding | 4.41B |
| Float | 4.43B |
| Short % of Float | +0.34% |
Source: Nexqual, June 9, 2026 at 23:43 UTC.
Leadership (HLN)
HLN is led by Brian James McNamara (age 59), CEO & Executive Director, per Nexqual as of June 9, 2026 at 23:43 UTC.
| CEO & Executive Director | Brian James McNamara (age 59) |
|---|---|
| CFO & Director | Dawn Amanda Allen (age 57) |
| Chief Marketing Officer | Tamara Jane Rogers (age 57) |
| President of EMEA & LatAm | Filippo Lanzi |
| President of Asia Pacific | Keith Choy (age 56) |
Major Backers & Investors (HLN)
Notable institutional backers of HLN include Dodge & Cox Inc., FMR, LLC, Fidelity, according to Nexqual as of June 9, 2026 at 23:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 5.99% |
| FMR, LLC | 2.57% |
| Fidelity | 1.33% |
| ClearBridge Investments, LLC | 0.72% |
| Harris Associates L.P. | 0.61% |
| Morgan Stanley | 0.43% |
| Harding Loevner LP | 0.35% |
| Arrowstreet Capital, Limited Partnership | 0.33% |
Source: Nexqual, June 9, 2026 at 23:43 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OGN | Organon & Co. | USD 13.4 | ▲ 0.3% |
| KVUE | Kenvue Inc. | USD 17.92 | ▲ 1.19% |
| VTRS | Viatris Inc. | USD 16.2 | ▲ 2.02% |
| ELAN | Elanco Animal Health Incorporat | USD 24.5 | ▲ 3.68% |
| GSK | GSK plc | USD 51.25 | ▼ 0.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:43 UTC. This page is informational and not investment advice.